In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point

1. Alkorta, M.
2. Giménez, M.J.
3. Vicente, D.
4. Aguilar, L.
5. Pérez-Trallero, E.